PatientsVille.com Logo


Thrombosis Medical Research Studies

Up-to-date List of Thrombosis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Thrombosis Medical Research Studies

Rank Status Study
1 Unknown  Residual Vein THROMBOSIS and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein THROMBOSIS
Conditions: Deep Vein THROMBOSIS;   Cancer
Intervention: Drug: low molecular weight heparin
Outcome Measures: Recurrent Deep Vein THROMBOSIS and/or Pulmonary Embolism;   Minor bleeding;   Death due to cancer
2 Not yet recruiting PREVENtion of HeartMate II Pump THROMBOSIS
Condition: HeartMate II Pump THROMBOSIS
Intervention: Other: Clinical Management Recommendations for reducing pump THROMBOSIS
Outcome Measures: Incidence of confirmed pump THROMBOSIS within three months of HeartMate II (HM II) implantation;   Incidence of confirmed pump THROMBOSIS within six months of HM II implantation;   Incidence of suspected pump THROMBOSIS (including unexplained hemolysis) within three and six months of HM II implantation;   Incidence of pump exchange, urgent transplantation or death due to pump THROMBOSIS within three and six months of HM II implantation;   Survival on LVAD support at six months post HM II implantation;   Multivariate analysis of risk factors for pump THROMBOSIS including demographics, anti-coagulation regimen, selected laboratory data (INR, LDH, plasma free Hgb), pump position measures, pump parameters and blood pressure;   Subgroup analysis of subjects identified as having a hypercoagulable disorder prior to HM II implantation;   Characterization of pump position in the study population (measured via quantitative assessment of X-ray images including inflow cannula angle, outflow cannula angle and pump pocket depth);   Characterization of selected lab values (INR, LDH and plasma free Hgb) within the study population;   Incidence of protocol-defined anticipated adverse events;   Characterization of pump parameters in the study population including power (watts), speed (rpm), flow (L/min), and pulsatility index
3 Unknown  Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein THROMBOSIS (DVT)
Condition: Deep Vein THROMBOSIS
Outcome Measures: The agreement between physician performed ultrasound and formal duplex ultrasonography for detection of proximal deep vein THROMBOSIS.;   Subgroup analysis: location of thrombus (proximal or distal);   Subgroup analysis: number of days in the hospital prior to exam;   Subgroup analysis: body mass index (BMI);   Subgroup analysis: weight gain from admission to the time of the exam;   Subgroup analysis: training level of examiner;   Subgroup analysis: difficulty of exam;   Subgroup analysis: specific examiner;   Subgroup analysis: presence or absence of calf vein THROMBOSIS;   Subgroup analysis: presence or absence of pulmonary embolism;   Subgroup analysis: DVT location;   Subgroup analysis: calf vein THROMBOSIS
4 Unknown  Rosuvastatin for Preventing Deep Vein THROMBOSIS
Conditions: Deep Vein THROMBOSIS;   Venous;   THROMBOSIS;   Prevention
Interventions: Drug: Rosuvastatin 20mg/d for 14days;   Drug: enoxaparin only
Outcome Measures: Development of deep vein THROMBOSIS diagnosed and confirmed by CT angiography at lower extremities;   D-dimer, lipid panel (Total cholesterol, TG, HDL, LDL), hsCRP, CK, transaminase, ALP
5 Recruiting Prevalence and Predictive Factors of Portal Vein THROMBOSIS in Patients With Cirrhosis
Conditions: Liver Cirrhosis;   Portal Vein THROMBOSIS
Outcome Measures: Presence of portal vein THROMBOSIS;   Cirrhosis Complications;   Incidence of portal vein THROMBOSIS;   mortality
6 Recruiting Two Weeks of Low Molecular Weight Heparin for Distal Vein THROMBOSIS
Conditions: Venous THROMBOSIS;   Pulmonary Embolism
Intervention: Drug: Enoxaparin
Outcome Measures: Symptomatic recurrence of venous THROMBOSIS (DVT, non fatal and fatal pulmonary embolism) within 3 months.;   Asymptomatic proximal thrombus extension at 2 weeks;   Time course of symptom resolution and the proportion of patients with complete resolution at two weeks.;   All-cause mortality;   Post-thrombotic syndrome;   Predictors of recurrent or progressive DVT or new PE
7 Recruiting Venous Vascularization and Inflammation on Contrast-enhanced Ultrasound (CEUS) in Patients With THROMBOSIS
Intervention: Other: No intervention
Outcome Measures: Venous perivascular vascularization and inflammation;   Inflammatory markers;   Edema of the lower extremity
8 Recruiting Thrombin Generation and Thrombus Degradation in Cerebral Venous THROMBOSIS : Clinical and Radiological Correlations
Condition: Cerebral Venous THROMBOSIS
Outcome Measures: Evolution of thrombin generation parameters;   Evolution of D Dimers concentration;   Evolution of thrombin generation parameters after end of treatment;   MR Imaging and Thrombin generation parameters;   MR Imaging and D Dimers concentration;   Evolution of D Dimers concentration after treatment
9 Recruiting Optimal Duration of Anticoagulation in Deep Venous THROMBOSIS
Conditions: Deep Venous THROMBOSIS of the Lower Extremities;   Symptomatic Recurrent Venous Thromboembolism
Intervention: Drug: Sodium warfarin
Outcome Measures: Recurrent venous thromboembolism (VTE);   Development of clinically relevant bleeding complications;   Development of clinically relevant bleeding complications occurring during the only period of anticoagulation
10 Recruiting Acute Venous THROMBOSIS: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Conditions: Deep Vein THROMBOSIS;   Venous THROMBOSIS;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Outcome Measures: Cumulative incidence of Post-Thrombotic Syndrome (Villalta Scale);   Severity of post thrombotic syndrome, resolution of presenting DVT symptoms, the prevalence of valvular reflux and residual thrombus, the degree of clot lysis, and cost-effectiveness.;   Major bleeding, symptomatic pulmonary embolism, recurrent venous thromboembolism, and death
11 Unknown  Bridging Therapy in Patients at High Risk for Stent THROMBOSIS Undergoing Surgery
Conditions: Bleeding;   THROMBOSIS
Outcome Measures: In-stent THROMBOSIS as assessed by acute coronary syndromes of unstable angina/non-ST elevation myocardial infarction or ST-elevation myocardial infarction during the hospitalization.;   Platelet function using the Verify Now device: T1 - at admission (2-3 days after the D/C of Plavix and prior to initiation of Aggrastat infusion); T2 - > 8 hours after initiation of Aggrastat; T3 - pre-operative; T4 - post loading dose of clopidogrel.;   Bleeding as assessed by hematocrit values obtained immediately pre-operative, immediately post-operative, and prior to discharge In addition, the use of blood products (pRBCs, platelets, FFP) will be assessed.
12 Recruiting The Designer D-dimer Deep Vein THROMBOSIS Diagnosis (4D) Study
Condition: Suspected Deep Vein THROMBOSIS
Outcome Measures: Confirmed symptomatic proximal Deep Vein THROMBOSIS;   Clinical Pretest Probability/ D-dimer/ Compression Ultrasound subgroups;   Death
13 Recruiting Pot-Kast: THROMBOSIS Prophylaxis After Knee Arthroscopy
Conditions: Deep Venous THROMBOSIS;   Pulmonary Embolism
Intervention: Drug: LMWH
Outcome Measures: Symptomatic deep venous THROMBOSIS (DVT);   Pulmonary Embolism (PE);   Major Bleeding;   Other clinically relevant bleeding;   Surgical site infection
14 Recruiting PRESTIGE: PREvention of Stent THROMBOSIS by an Interdisciplinary Global European Effort
Condition: Coronary Artery Stent THROMBOSIS
Outcome Measure: to identify novel factors responsible for the occurence of stent THROMBOSIS
15 Recruiting Thrombolysis or Anticoagulation for Cerebral Venous THROMBOSIS
Condition: Sinus THROMBOSIS, Intracranial
Interventions: Drug: Endovascular thrombolysis;   Drug: Heparin
Outcome Measures: Favorable clinical outcome (modified Rankin score 0-1);   Recanalization rate of cerebral venous system;   All cause mortality;   Required surgical intervention in relation to CVT;   Major extracranial and symptomatic intracranial hemorrhagic complications;   Dead or dependency (modified Rankin score 3-6)
16 Recruiting Pot-Cast: THROMBOSIS Prophylaxis During Plaster Cast Lower Leg Immobilisation
Conditions: Deep Venous THROMBOSIS;   Pulmonary Embolism
Intervention: Drug: LMWH
Outcome Measures: Symptomatic deep venous THROMBOSIS (DVT);   Pulmonary Embolism (PE);   Major Bleeding;   Other clinically relevant bleeding;   Surgical site infection
17 Not yet recruiting Evaluation of Portal Venous System THROMBOSIS After Blunt Splenic Trauma Utilizing Doppler Ultrasound
Condition: THROMBOSIS of Portal Venous System.
Intervention: Other: Doppler Ultrasound
Outcome Measures: Utilizing doppler ultrasound to assess the presence of partial or complete THROMBOSIS in the portal venous system (splenic vein, superior mesenteric vein, inferior mesenteric vein and/or portal vein) after blunt splenic trauma.;   Utilizing follow-up doppler ultrasound to assess change in the presence of partial or complete THROMBOSIS in the portal venous system (splenic vein, superior mesenteric vein, inferior mesenteric vein and/or portal vein) after blunt splenic trauma.
18 Not yet recruiting Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related THROMBOSIS
Conditions: Venous THROMBOSIS;   Neoplasms
Intervention: Drug: Heparin, Low-Molecular-Weight
Outcome Measure: Feasibility
19 Recruiting Evaluation of the Duration of Therapy for THROMBOSIS in Children
Condition: Venous THROMBOSIS
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention;   Drug: Dalteparin
Outcome Measures: Bivariate endpoint.;   Prevalence/severity of post-thrombotic syndrome.
20 Recruiting Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous THROMBOSIS
Conditions: Deep Vein THROMBOSIS;   Pulmonary Embolism
Intervention: Drug: Rosuvastatin
Outcome Measure: Coagulation factor VIII

These studies may lead to new treatments and are adding insight into Thrombosis etiology and treatment.

A major focus of Thrombosis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Thrombosis